2,754 Shares in Colgate-Palmolive (NYSE:CL) Purchased by D Orazio & Associates Inc.

D Orazio & Associates Inc. purchased a new stake in shares of Colgate-Palmolive (NYSE:CL) in the second quarter, according to the company in its most recent filing with the SEC. The fund purchased 2,754 shares of the company’s stock, valued at approximately $267,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. E Fund Management Hong Kong Co. Ltd. purchased a new position in Colgate-Palmolive during the second quarter worth about $25,000. Union Savings Bank boosted its stake in shares of Colgate-Palmolive by 76.6% in the 4th quarter. Union Savings Bank now owns 309 shares of the company’s stock worth $25,000 after buying an additional 134 shares during the last quarter. PSI Advisors LLC grew its holdings in shares of Colgate-Palmolive by 4,971.4% in the first quarter. PSI Advisors LLC now owns 355 shares of the company’s stock valued at $32,000 after acquiring an additional 348 shares in the last quarter. Continuum Advisory LLC increased its position in shares of Colgate-Palmolive by 46.5% during the second quarter. Continuum Advisory LLC now owns 394 shares of the company’s stock valued at $38,000 after acquiring an additional 125 shares during the last quarter. Finally, Atlantic Edge Private Wealth Management LLC bought a new stake in Colgate-Palmolive during the fourth quarter worth $32,000. 80.41% of the stock is owned by institutional investors.

Colgate-Palmolive Price Performance

Colgate-Palmolive stock opened at $106.09 on Thursday. The stock has a market cap of $87.04 billion, a price-to-earnings ratio of 33.57, a PEG ratio of 3.78 and a beta of 0.40. The company has a quick ratio of 0.70, a current ratio of 1.06 and a debt-to-equity ratio of 16.90. The business has a 50-day simple moving average of $101.72 and a 200 day simple moving average of $94.96. Colgate-Palmolive has a 52 week low of $67.62 and a 52 week high of $109.30.

Colgate-Palmolive (NYSE:CL) last issued its quarterly earnings data on Friday, July 26th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.87 by $0.04. The company had revenue of $5.06 billion during the quarter, compared to analyst estimates of $5 billion. Colgate-Palmolive had a return on equity of 470.19% and a net margin of 14.21%. Colgate-Palmolive’s revenue was up 4.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.77 earnings per share. On average, research analysts forecast that Colgate-Palmolive will post 3.57 earnings per share for the current fiscal year.

Insider Transactions at Colgate-Palmolive

In other news, insider Sally Massey sold 15,850 shares of the company’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $103.28, for a total value of $1,636,988.00. Following the completion of the transaction, the insider now directly owns 13,942 shares in the company, valued at approximately $1,439,929.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Panagiotis Tsourapas sold 14,794 shares of Colgate-Palmolive stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $102.94, for a total value of $1,522,894.36. Following the transaction, the insider now owns 5,146 shares in the company, valued at $529,729.24. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Sally Massey sold 15,850 shares of the stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $103.28, for a total value of $1,636,988.00. Following the sale, the insider now owns 13,942 shares of the company’s stock, valued at $1,439,929.76. The disclosure for this sale can be found here. In the last ninety days, insiders sold 43,490 shares of company stock valued at $4,486,063. Insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

CL has been the subject of a number of recent analyst reports. Barclays raised their target price on Colgate-Palmolive from $91.00 to $96.00 and gave the company an “equal weight” rating in a research report on Monday, July 29th. Stifel Nicolaus lifted their price objective on shares of Colgate-Palmolive from $95.00 to $105.00 and gave the stock a “buy” rating in a research report on Monday, July 22nd. UBS Group increased their target price on shares of Colgate-Palmolive from $119.00 to $122.00 and gave the company a “buy” rating in a research report on Wednesday, September 4th. Deutsche Bank Aktiengesellschaft cut shares of Colgate-Palmolive from a “buy” rating to a “hold” rating and lifted their price target for the stock from $107.00 to $109.00 in a report on Monday. Finally, Morgan Stanley increased their price objective on Colgate-Palmolive from $103.00 to $111.00 and gave the company an “overweight” rating in a report on Monday, July 29th. Nine research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, Colgate-Palmolive currently has a consensus rating of “Moderate Buy” and an average target price of $102.63.

Colgate-Palmolive Profile

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.